Horsten Fien, Gillemot Sarah, Calò Pierluigi, Mazilier Pauline, Maes Piet, Snoeck Robert, Andrei Graciela
Molecular, Structural and Translational Virology Research Group, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Department of Pediatric oncology and Bone marrow transplantation, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Hôpital universitaire des Enfants Reine Fabiola, Brussels, Belgium.
NPJ Antimicrob Resist. 2025 May 28;3(1):43. doi: 10.1038/s44259-025-00118-y.
Cytomegalovirus (CMV) infection is a common complication in newborns with severe combined immunodeficiency (SCID). Prolonged antiviral treatment in immunocompromised patients increases the risk of the emergence of drug resistance. We analyzed drug resistance in a newborn with SCID who developed neonatal CMV infection. Sequencing of viral DNA polymerase (DP; UL54), protein kinase (UL97), and terminase (UL51, UL56, UL89) genes identified ganciclovir (GCV) and foscarnet (PFA) resistance mutations in blood, but not cerebrospinal fluid. After treatment was shifted to cidofovir and letermovir (LMV), a LMV resistance mutation rapidly emerged in UL56 (C325F). Eventually, a multidrug-resistant genotype was established (DP-V781I and UL56-C325F). Whole-genome sequencing of CMV in clinical blood samples showed an otherwise stable genotype. This case describes a CMV infection complicated by compartmentalization and the emergence of resistance to GCV, PFA, and LMV. It highlights the need for further investigation into alternative antiviral strategies for the prevention and treatment of CMV.
巨细胞病毒(CMV)感染是重症联合免疫缺陷(SCID)新生儿的常见并发症。免疫功能低下患者长期进行抗病毒治疗会增加耐药性出现的风险。我们分析了一名患新生儿CMV感染的SCID新生儿的耐药情况。对病毒DNA聚合酶(DP;UL54)、蛋白激酶(UL97)和末端酶(UL51、UL56、UL89)基因进行测序,在血液中发现了更昔洛韦(GCV)和膦甲酸钠(PFA)耐药突变,但脑脊液中未发现。治疗改为西多福韦和来特莫韦(LMV)后,UL56(C325F)中迅速出现了LMV耐药突变。最终,建立了多重耐药基因型(DP-V781I和UL56-C325F)。临床血液样本中CMV的全基因组测序显示基因型在其他方面是稳定的。该病例描述了CMV感染并发区室化以及对GCV、PFA和LMV耐药的出现。它强调了需要进一步研究预防和治疗CMV的替代抗病毒策略。